Fan, Y., Dong, X., Wang, M., Shi, Y., Wang, K., Li, E., Wu, Y. (2026). Liposomal irinotecan plus sintilimab and lenvatinib for second-line advanced HER2-negative gastric/gastro-esophageal junction adenocarcinoma: A phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e16035